Impact of intestinal microbiome on infections, course and outcome of haematological-oncological patients treated with chemotherapy
- Conditions
- gut microbiomeC92.0Acute myeloblastic leukaemia [AML]
- Registration Number
- DRKS00011674
- Lead Sponsor
- niversitätsklinikum Magdeburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
1.Age =18 years;
2.Written informed consent;
3.AML first diagnose;
4.Therapy with repetitive chemotherapy cycles, inclusive allogeneic or autologous stem cell transplantation
Exclusion Criteria
1.Antibiotic therapy =4 weeks before study inclusion;
2.AML teatment with cytoreductive long-term therapy (e. g. hydroxyurea);
3.Stool transplantation (e. g. due to relapsed C. difficile infection)
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Changes of intestinal microbiome after chemtherapy
- Secondary Outcome Measures
Name Time Method 1. Impact on course and outcome of disease;<br>2. Association between mixture of microbiome and MRGN colonisation or infection<br>